Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Exscientia Ltd.. (8/5/19). "Press Release: Sanofi Exercises Option on Exscientia-designed Bispecific Small Molecule for Treatment of Immunological Conditions".

Organisations Organisation Exscientia Ltd. (ex scientia)
  Group Exscientia (Group)
  Organisation 2 Sanofi S.A. (Euronext: SAN, Nasdaq: SNY)
  Group Sanofi (Group) [since May 2011]
Products Product AI-based drug discovery software
  Product 2 small-molecule drug
Index term Index term Sanofi–Exscientia: drug discovery, 201705– strategic research collab up to €250m using AI for bi-specific small-moleulces for metabolic disease
Persons Person Hopkins, Andrew (Ex Scientia 201604 CEO)
  Person 2 Swindells, Mark (Exscientia 201901 COO)

AI Design enables new bispecific small molecule modality

Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, today announced that Sanofi has exercised its option to progress an innovative Bispecific Small molecule project it discovered as part of its new modality collaboration. The novel, first-in-class, bispecific investigational small molecule targets two distinct, biologically validated pathways related to inflammation and the progression of fibrosis.

Commenting on this relationship, Andrew Hopkins (CEO, Exscientia) said: “We are delighted that Sanofi has exercised this option to advance a key collaboration program. The opportunity identified with Sanofi focuses on two highly relevant disease targets where normally two separate molecules would be required to achieve the relevant therapeutic effect. Our AI-driven systems, coupled with integrated chemistry and assay resource from Sanofi, identified a single small molecule, with integrated pharmacophore, capable of interacting productively with both targets. To our knowledge the Exscientia platform is the only system capable of implementing such designs.”

Bispecific Small Molecules are a new concept where a single compound is designed to productively interact with two distinct drug targets, instead of requiring two independent compounds. In contrast with previous approaches, where relatively large bi-functional compounds were made by tethering two existing molecules together with a linker, Exscientia has pioneered the discovery of Bispecific Small Molecules that simultaneously fulfil the binding site requirements of two targets through an integrated pharmacophore. Due to their low molecular weight Bispecific Small Molecules are suitable for oral delivery.

Over the past two years Exscientia has generated nearly 100 billion novel compounds through evolutionary design (six orders of magnitude larger than searching for hit molecules using conventional HTS) to specifically explore bispecific small molecule opportunities for over one thousand disease-relevant target combinations in the areas of metabolic disease and fibrosis. Those with the strongest potential were synthesised and validated experimentally by Sanofi to confirm Exscientia’s dual target hypothesis.

This exercise option is the result of two years of work identifying promising dual target opportunities. For the licensed programme reaching agreed delivery criteria, a series of development and sales milestones may be payable by Sanofi.

The 2017 partnership announcement can be accessed here.

About Exscientia

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

Exscientia’s innovative Centaur Chemist™ platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds are automatically designed and prioritised for synthesis by its AI systems, which rapidly evolve compounds towards the desired candidate criteria for clinical development.

Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and

pharmacokinetic criteria. As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.

Exscientia is collaborating with several leading pharmaceutical and life sciences companies, including Celgene, GSK, Sanofi, Roche and Evotec.

Exscientia has its headquarters in Oxford, UK with offices in the UK, USA and Japan. For more information visit us on or follow us on Twitter @exscientialtd

Media enquiries:
Edelman PR
Sesh Rahim +44(0) 203 0474207
Camille Oster +44(0) 7812660934

Corporate enquiries:
Mark Swindells - Chief Commercial Officer

Record changed: 2019-08-22


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Exscientia (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] Made Without Love 650x80px

» top